Navigation Links
BioCryst Announces Pricing of Public Offering of Common Stock
Date:11/19/2009

BIRMINGHAM, Ala., Nov. 19 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the pricing of a public offering of 5,000,000 shares of its common stock at $9.75 per share, resulting in gross proceeds of $48.75 million. All of the shares are being offered by BioCryst pursuant to an effective shelf registration statement previously filed with the Securities and Exchange Commission. BioCryst has also granted the underwriters a 30-day option to purchase up to an aggregate of 750,000 additional shares of common stock to cover over-allotments, if any. Morgan Stanley is acting as the sole book-runner for the offering, with JMP Securities and Oppenheimer & Co. acting as co-managers. The offering is expected to close on November 25, 2009.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale is not permitted. The offering of these securities is being made only by means of a prospectus supplement and accompanying prospectus, copies of which may be obtained from Morgan Stanley & Co. Incorporated, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, telephone: (866) 718-1649, or by emailing prospectus@morganstanley.com.

The issuer has filed a registration statement (including a base prospectus) with the Securities and Exchange Commission, or SEC, for an offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and related prospectus supplements and other documents that the issuer has filed or will file with the SEC for more complete info
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BioCryst Initiates Enrollment in Pivotal Trial of Forodesine HCL in Patients with Cutaneous T-Cell Lymphoma (CTCL)
2. BioCryst Provides Forodesine HCl Update
3. BioCryst Updates Peramivir Clinical Development Plan
4. BioCryst Announces Initiation of Phase II Study of Intramuscular Peramivir for the Treatment of Seasonal Influenza
5. BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
6. BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009
7. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
8. BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
9. BioCryst Provides Update Regarding Peramivir for Influenza
10. BioCryst Clarifies Government Declaration Regarding Peramivir
11. BioCryst to Present at JMP Securities Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... BRIDGEWATER, N.J. , Sept. 16, 2014 /PRNewswire/ ... pharmaceutical company focused on developing and commercializing therapeutic ... renal and infectious diseases, announces the amendment and ... and E preferred stock and related warrants, as ... 2014 common stock and warrant financing, to remove ...
(Date:9/16/2014)... Sept. 16, 2014  Relmada Therapeutics, Inc., (OTCBB: RLMD), ... of chronic pain, announced today that it has entered ... (MSKCC) in a series of animal studies for levorphanol, ... extended release form of levorphanol.  Gavril Pasternak, MD, PhD, ... Dr. Pasternak said, "Levorphanol is a ...
(Date:9/15/2014)... , Sept. 16, 2014 The French ... (HNF) announced today an agreement to collaborate on programs ... support the development of a stronger CMT patient and ... support to several HNF,s initiatives including: , ... the HNF website featuring  HNF newsletters, materials and latest ...
Breaking Medicine Technology:CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 2CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 3Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 2Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 3Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 2Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 3Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 4
(Date:9/16/2014)... Tara Haelle ... News) -- About 14.5 million U.S. cancer survivors are ... the American Association for Cancer Research reported Tuesday. ... and include nearly 380,000 survivors of childhood cancer, according ... advances in prevention, identification, research and treatment of cancer ...
(Date:9/16/2014)... New York (PRWEB) September 16, 2014 ... ) filed against C.R. Bard, Inc. continue to ... in U.S. District Court, Southern District of West ... Order dated September 15, 2014, the Court has ... beneficial to the proceeding. The Order indicates that ...
(Date:9/16/2014)... Danny Dreyer, ChiRunning & ChiWalking founder ... events throughout the U.S. Dreyer is one of the ... taught a full circuit of nationwide workshops since 2004. ... tracks at his workshops so participants of all levels ... techniques. , Workshop schedule: , ,     September ...
(Date:9/16/2014)... One in five American men admits to using ... survey shows. A nationally representative study from ... is more prevalent than diabetes. This violence includes ... hitting, kicking, biting, choking, burning or threatening their ... Although abuse by high-profile professional athletes has recently ...
(Date:9/16/2014)... The Wistar Institute,s Meenhard Herlyn, D.V.M., D.Sc., is ... Program of Research Excellence (SPORE) grant, a prestigious ... researchers at Wistar and the University of Pennsylvania ... this SPORE is to translate fundamental laboratory discoveries ... melanoma and other skin cancers. , Melanoma is ...
Breaking Medicine News(10 mins):Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 2Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 3Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 4Health News:Vaginal Mesh Lawsuit News: Discovery Conferences Scheduled for Federal Transvaginal Mesh Lawsuits Filed Against C.R. Bard, Bernstein Liebhard LLP Reports 2Health News:Vaginal Mesh Lawsuit News: Discovery Conferences Scheduled for Federal Transvaginal Mesh Lawsuits Filed Against C.R. Bard, Bernstein Liebhard LLP Reports 3Health News:Vaginal Mesh Lawsuit News: Discovery Conferences Scheduled for Federal Transvaginal Mesh Lawsuits Filed Against C.R. Bard, Bernstein Liebhard LLP Reports 4Health News:Join ChiRunning® Founder, Danny Dreyer, on Fall 2014 US Workshop 2Health News:Join ChiRunning® Founder, Danny Dreyer, on Fall 2014 US Workshop 3Health News:1 in 5 U.S. Men Admits to Violence Against Spouse, Partner 2Health News:Wistar and Penn Medicine collaborate on $12.1 million SPORE grant in melanoma 2Health News:Wistar and Penn Medicine collaborate on $12.1 million SPORE grant in melanoma 3
... disturbing implications for the government, pension companies and life ... warning that increases in longevity translate into bad news ... look after us when we are old; to make ... uncertain. , Kevin Dowd, Professor of Financial Risk Management ...
... 29th 2007 With the genomic revolution radical improvement ... cancer. This is of the utmost importance, since the ... detection. In a special issue of Disease Markers, published ... the identification and understanding of biomarkers for epithelial ovarian ...
... found incidentally during a CT scan, and the masses ... according to a recent study conducted by researchers at ... increased utilization of CT, we are frequently encountering findings ... scanned, the so called incidentalomas, of which adrenal masses ...
... winning program at the Best Practices in Consumer ... 25-26, 2008, WASHINGTON, Nov. 29 Today ... selected the finalists for its,inaugural Best Practices in ... attracted entries detailing,innovative and proven programs that are ...
... Revolutionary new intimacy creme aids women in greater ... Passion Parties, Inc. is excited to,add the new ... cornerstone of the Passion Parties product line complete ... the G-Spot Creme instills a,positive level of confident ...
... Signs contract with Best Medical International Inc., ... leading,provider of medical isotopes and radiopharmaceuticals, today signed ... its external beam,therapy and self-contained irradiator product lines. ... growth strategy to focus its resources on being ...
Cached Medicine News:Health News:URAC Names Medco as a Finalist in First-ever Best Practices in Consumer Empowerment and Protection Awards 2Health News:URAC Names Medco as a Finalist in First-ever Best Practices in Consumer Empowerment and Protection Awards 3Health News:Passion Parties Hits the Spot 2Health News:MDS Nordion Divests Non Strategic Product Lines 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: